{"groups":[{"description":"Gabapentin liquid by mouth or per Tube 300mg twice a day","id":"FG000","title":"Gabapentin"},{"description":"Placebo liquid by mouth or Per Tube twice a day","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Nausea"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Remain intubated"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Change in surgery plan"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"Change to outpatient status"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Return to operating room"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Delirium"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"55"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"13 participants were enrolled but withdrew prior to study participation with no medication given. 8 participants withdrew due to patient preference and 5 withdrew due to cancellation of surgery.","recruitmentDetails":"The study opened to participant enrollment on 06/24/2016 and closed to participant enrollment on 06/30/2017."}